Loading...
XNASURGN
Market cap456mUSD
Dec 24, Last price  
10.82USD
1D
1.03%
1Q
-15.86%
IPO
-22.71%
Name

Urogen Pharma Ltd

Chart & Performance

D1W1MN
XNAS:URGN chart
P/E
—
P/S
5.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.85%
Rev. gr., 5y
136.08%
Revenues
83m
+28.52%
00017,530,0008,158,0001,128,00018,00011,799,00048,042,00064,357,00082,713,000
Net income
-102m
L-6.34%
-3,306,000-4,557,000-12,689,000-1,941,000-20,000,000-75,657,000-100,530,000-128,484,000-110,820,000-109,163,000-102,244,000
CFO
-76m
L-12.77%
-2,557,000-4,117,000-7,175,0004,189,000-9,571,000-37,334,000-71,017,000-105,886,000-84,892,000-87,559,000-76,376,000
Earnings
Mar 12, 2025

Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URL
https://www.urogen.com/
IPO date
May 04, 2017
Employees
193
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
82,713
28.52%
64,357
33.96%
48,042
307.17%
Cost of revenue
54,975
60,560
52,799
Unusual Expense (Income)
NOPBT
27,738
3,797
(4,757)
NOPBT Margin
33.54%
5.90%
Operating Taxes
3,920
1,135
1,449
Tax Rate
14.13%
29.89%
NOPAT
23,818
2,662
(6,206)
Net income
(102,244)
-6.34%
(109,163)
-1.50%
(110,820)
-13.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
67,358
1,351
(83)
BB yield
-15.57%
-0.67%
0.04%
Debt
Debt current
941
3,330
Long-term debt
100,239
100,709
796
Deferred revenue
(2,842)
Other long-term liabilities
112,916
98,923
88,555
Net debt
(41,231)
1,464
(86,363)
Cash flow
Cash from operating activities
(76,376)
(87,559)
(84,892)
CAPEX
(194)
(254)
(752)
Cash from investing activities
(953)
1,060
4,069
Cash from financing activities
116,931
97,134
72,319
FCF
29,356
1,880
(10,124)
Balance
Cash
136,968
99,963
89,814
Long term investments
4,502
223
675
Excess cash
137,334
96,968
88,087
Stockholders' equity
(679,247)
(577,148)
(467,285)
Invested Capital
826,346
687,394
565,139
ROIC
3.15%
0.43%
ROCE
18.86%
3.35%
EV
Common stock shares outstanding
28,834
22,807
22,347
Price
15.00
69.11%
8.87
-6.73%
9.51
-47.23%
Market cap
432,515
113.80%
202,296
-4.81%
212,525
-45.85%
EV
391,284
203,760
126,162
EBITDA
29,443
5,614
(2,984)
EV/EBITDA
13.29
36.30
Interest
14,715
8,438
17,444
Interest/NOPBT
53.05%
222.23%